Navigation Links
Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
Date:2/4/2008

ANN ARBOR, Mich., Feb. 4 /PRNewswire/ -- Pfizer's loss of some top talent, including Lipitor pioneer Dr. Bob Sliskovic, is the gain of two Michigan companies teaming to help speed research to fight bone diseases such as multiple myeloma, metastatic bone disease, rheumatoid arthritis and osteoporosis.

Velcura Therapeutics President and CEO Michael W. Long, PhD, announced his biotechnology company will work with Dr. Sliskovic and International Discovery Sourcing Consultants, LLC (IDSC), on the design and sourcing of medicinal chemistry data for its second generation and new bone therapy molecules. "IDSC brings added drug discovery leadership, experienced vendors and project managers as we begin our clinical trial this year for VEL-0230, a new drug that stimulates bone formation and inhibits bone loss," said Long.

"We offer in-depth support for scientific programs and also welcome a long-term partnership with firms like Velcura that are outsourcing," said IDSC President and CEO Mark Creswell. "The pharmaceutical industry experts joining us from Pfizer have 17-30 years of experience; we have chaired multiple projects that moved drug candidates into the clinic," he added. "Bob Sliskovic, for example, was responsible for the development of some 30 clinical candidates, including Lipitor."

Dr. Sliskovic, who was featured in the Dec. 11, 2007 Wall Street Journal, now dreams of being involved in another blockbuster like Lipitor. The work that he is doing now with IDSC could help Velcura to develop a treatment to help millions of individuals suffering from bone diseases like Osteoporosis, which is second to heart disease as a world health problem.

About Velcura Therapeutics(R), Inc.

Velcura Therapeutics Inc. is an early-stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to better understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, dual-acting therapies that demonstrate both anabolic bone-building and anti- bone-loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize compounds that both simulate and inhibit bone growth. Velcura's lead compound, VEL-0230 was identified using these bone assays and will begin the first in-man clinical trials this month after Velcura recently completed a successful Investigational New Drug application (IND) to the U.S. Food and Drug Administration. More information is at http://www.velcura.com

About International Discovery Sourcing Consultants (IDSC)

International Discovery Sourcing Consultants is an innovative pharmaceutical drug discovery and development service provider based in Chelsea, Michigan. IDSC was formed in 2007 by a former Pfizer director Mark Creswell who has more than 20 years experience including leading a Big Pharma Discovery Chemistry Outsourcing Program. IDSC services include Drug Discovery Consulting, Interim Leadership and Project Management as well as Outsourcing Project Management, Outsourcing Consulting, Raw Material Sourcing, and Harmonized Tariff Code Assignment. For more information visit http://www.idscbiotechnetwork.com .
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215


'/>"/>
SOURCE Velcura Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
2. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
3. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
4. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
5. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
6. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
7. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
8. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
9. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
10. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
11. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
(Date:12/8/2016)... Dec. 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: ... develops and plans to commercialize innovative therapeutics for ... common stock were approved for trading on the ... on the OTCQX, effective today, under the ticker ... OTCQX market, companies must meet high financial standards, ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)... 8, 2016   Biocept, Inc . (NASDAQ: ... of clinically actionable liquid biopsy tests to improve ... data featuring its Target Selectorâ„¢ Circulating Tumor Cell ... the detection of actionable biomarkers in patients with ... by Sara Cannon Research Institute (SCRI), the research ...
Breaking Biology Technology:
(Date:12/2/2016)... December 1, 2016 The ... Voice), Future Technology (Iris Recognition System), Vehicle Type ... Global Forecast to 2021", published by MarketsandMarkets, the ... in 2016, and is projected to grow to ... of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... 2016   Neurotechnology , a provider ... technologies, today released FingerCell 3.0, a software ... that run on low-power, low-memory microcontrollers. FingerCell ... than 128KB of memory, enabling it to ... limited on-board resources, such as: mobile phones, ...
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... LiveWire Healthcare and Life Sciences Awards as "Most ... off an unprecedented year of recognition and growth for ... over 15 years. iMedNet ™ ...
Breaking Biology News(10 mins):